277 related articles for article (PubMed ID: 10807351)
1. Gene therapy for head and neck cancer.
Gleich LL
Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility gene therapy: the importance of haplotype and beta 2-microglobulin.
Salamone FN; Gleich LL; Li YQ; Stambrook PJ
Laryngoscope; 2004 Apr; 114(4):612-5. PubMed ID: 15064612
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
Rini BI; Selk LM; Vogelzang NJ
Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
7. Alloantigen gene therapy for head and neck cancer: evaluation of animal models.
Gleich LL; Li YQ; Li S; Gluckman JL; Stambrook PJ
Head Neck; 2003 Apr; 25(4):274-9. PubMed ID: 12658731
[TBL] [Abstract][Full Text] [Related]
8. Technology evaluation: Allovectin-7, Vical.
Galanis E
Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
[TBL] [Abstract][Full Text] [Related]
9. High-dose intra-arterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck.
Wilson WR; Siegel RS; Harisiadis LA; Davis DO; Nguyen HH; Bank WO
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):809-12. PubMed ID: 11448355
[TBL] [Abstract][Full Text] [Related]
10. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial.
Gleich LL; Gluckman JL; Armstrong S; Biddinger PW; Miller MA; Balakrishnan K; Wilson KM; Saavedra HI; Stambrook PJ
Arch Otolaryngol Head Neck Surg; 1998 Oct; 124(10):1097-104. PubMed ID: 9776187
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
Grandis JR; Falkner DM; Melhem MF; Gooding WE; Drenning SD; Morel PA
Clin Cancer Res; 2000 Jul; 6(7):2794-802. PubMed ID: 10914726
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
13. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
[TBL] [Abstract][Full Text] [Related]
14. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
Spector JG; Sessions DG; Haughey BH; Chao KS; Simpson J; El Mofty S; Perez CA
Laryngoscope; 2001 Jun; 111(6):1079-87. PubMed ID: 11404625
[TBL] [Abstract][Full Text] [Related]
15. Head and neck cancer: the importance of oxygen.
Terris DJ
Laryngoscope; 2000 May; 110(5 Pt 1):697-707. PubMed ID: 10807350
[TBL] [Abstract][Full Text] [Related]
16. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck.
Moore BA; Weber RS; Prieto V; El-Naggar A; Holsinger FC; Zhou X; Lee JJ; Lippman S; Clayman GL
Laryngoscope; 2005 Sep; 115(9):1561-7. PubMed ID: 16148695
[TBL] [Abstract][Full Text] [Related]
17. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.
Goguen LA; Posner MR; Tishler RB; Wirth LJ; Norris CM; Annino DJ; Sullivan CA; Li Y; Haddad RI
Arch Otolaryngol Head Neck Surg; 2006 May; 132(5):526-31. PubMed ID: 16702569
[TBL] [Abstract][Full Text] [Related]
18. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
19. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
20. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
